Acute Radiation Syndrome
SNBL USA is in a unique position to perform ARS studies, from demonstration of efficacy in representative animal models, to pivotal nonclinical studies under the FDA’s Animal Efficacy Rule.
SNBL USA is committed to providing clients with quality you expect with your preclinical needs. We are committed to providing service you trust with the turnaround you need.
As a drug class, Nucleic Acid-based Therapeutics represents a diverse spectrum of chemistry, constructs, and delivery options.
Blending our strengths, SNBL USA’s laboratory services division represents a powerful resource to extend discovery and development capabilities while still providing superior, individualized service to each client.
Congratulations to our own Seattle Seahawks for a spectacular win in Sunday’s NFC Playoff game! We’re headed to the Super Bowl for the second year in a row – another unbelievable accomplishment! See you in Arizona on Sunday, February 1st. Go Hawks!Read More
PepTalk, hosted by Cambridge Health Institute, provides access to cutting-edge research in protein expression and analysis, and brings together many academic and industrial scientists, who have a very broad prospective on all the key subjects in the field. SNBL USA’s own, Dr. Michael Templin, Technical Director, is scheduled to present on January 23 @ 12:30 PM within the ‘Bispecific Antibody Therapeutics’ pipeline track. For more information, visit this page and scroll down to the 12:30 PM presentation: “After the Development Candidate has been selected: Successful...Read More
WILMINGTON, N.C., and TOKYO (December 24, 2014) – Pharmaceutical Product Development, LLC (PPD) and Shin Nippon Biomedical Laboratories Ltd. (SNBL) (TSE:2395) today announced an agreement to form a joint venture that will provide a full range of clinical development services in Japan, including Phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services. The joint venture, to be named PPD-SNBL, will result from the combination of SNBL’s clinical research division...Read More